Proteomics International (ASX:PIQ) share price jumps after diabetes study readouts

The biotechnology research company's share price is in the green today.

| More on:
Jumping asx share price represented by young girl smiling and jumping up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Proteomics International Laboratories Ltd (ASX: PIQ) share price has jumped firmly into the green today.

Shares in the Australian biotech company surged this morning and jumped 10% from the market open, before retreating back down. At the time of writing, Proteomics shares are trading at $1.08, up 8.04%.

The gains came following readouts from its collaborative study with Janssen Pharmaceuticals.

Let's take a closer look at what this study entailed and what it means for the company's share price.

What is Proteoimcs?

Proteomics is an Australian biotechnology and biological research company.

It has expertise in the domain of "proteomics", which is the study of the structure and function of various proteins. Hence the company name.

The company has patented a diabetes test called PromarkerD that predicts renal function in diabetes.

Drug candidate lowers diabetes test scores

Proteomics announced that its drug candidate canagliflozin reduced PromarkerD risk scores in patients with type-2 diabetes (T2DM).

PromarkerD is a blood test that accurately analyses and predicts renal function for those with T2DM.

It is the only test that can predict with a degree of certainty the onset of a condition known as diabetic kidney disease (DKD).

It, therefore, stands to reason that reductions in PromarkerD scores are an essential component in reducing the risk of DKD.

Proteomics' canagliflozin "was the first diabetes medicine with an indication to slow the progression of DKD" in T2DM in 2019.

The collaborative study confirmed that canagliflozin "significantly lowered PromarkerD risk scores" over a three-year period.

Speaking on the results, Proteomics' managing director Dr Richard Lipsombe said:

Now, for the first time, we are confirming that the [canagliflozin] SGLT2 inhibitor class of diabetes drug is associated with lowering a patient's PromarkerD risk score, and that there is a potential treatment for the at-risk patients identified by the test.

Investors seem to enjoy the company update, as its share price remains 8.04% into the green from market open.

Proteonomics share price snapshot

The Proteomics share price has posted a year to date return of 29%, extending the previous 12 month's return of 138%.

These returns have outpaced the S&P / ASX 200 Index (ASX: XJO)'s return of ~22% over the previous 1-year period.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Which beaten down ASX 200 share did Goldman Sachs just upgrade to a buy rating?

The broker has become more bullish on this stock following last week's update.

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Best Shares

The best ASX shares to invest $1,000 in right now

Analysts think that putting your money into these stocks could be a smart move.

Read more »

green etf represented by letters E,T and F sitting on green grass
Share Market News

4 ASX ETFs to buy for FY25 and beyond

Could these ETFs be top options for investors looking for long term picks?

Read more »

A smiling woman sips coffee at a cafe ready to learn about ASX investing concepts.

How I'd invest $10,000 in ASX shares right now

I’m bullish about the prospects of these stocks.

Read more »

A fortune teller looks into a crystal ball in an office surrounded by business people.
Share Market News

What's the outlook for shares vs. property in FY25?

Generally speaking, there is optimism among the experts for both shares and property in FY25.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Best Shares

Top ASX shares to buy before earnings season

It's almost time to take a look at the books!

Read more »

sad party goer sitting alone after celebration
Share Market News

Here are the top 10 ASX 200 shares today

The ASX 200 had a horrible end to its trading week this Friday.

Read more »

A young female investor sits in her home office looking at her ipad and smiling as she sees the QBE share price rising
Broker Notes

3 ASX shares brokers tip for significant outperformance in FY 2025

Leading brokers expect some significant outperformance from these three ASX shares.

Read more »